Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma-Reference-Cited by-同舟云学术

Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma

Published:2016-10-02 Issue:3 Volume:37 Page:423-433
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Pecorelli Anna¹,Lenzi Barbara²,Gramenzi Annagiulia²,Garuti Francesca²,Farinati Fabio³,Giannini Edoardo G.⁴,Ciccarese Francesca⁵,Piscaglia Fabio¹^ORCID,Rapaccini Gian Lodovico⁶,Di Marco Maria⁷,Caturelli Eugenio⁸,Zoli Marco⁹,Borzio Franco¹⁰,Sacco Rodolfo¹¹,Cabibbo Giuseppe¹²,Felder Martina¹³,Morisco Filomena¹⁴,Gasbarrini Antonio¹⁵,Baroni Gianluca Svegliati¹⁶,Foschi Francesco G.¹⁷,Biasini Elisabetta¹⁸,Masotto Alberto¹⁹,Virdone Roberto²⁰,Bernardi Mauro²,Trevisani Franco²,

Affiliation:

1. Dipartimento di Scienze Mediche e Chirurgiche; Unità di Medicina Interna; Alma Mater Studiorum - Università di Bologna; Bologna Italy

2. Dipartimento di Scienze Mediche Chirurgiche; Unità di Semeiotica Medica; Alma Mater Studiorum - Università di Bologna; Bologna Italy

3. Dipartimento di Scienze Chirurgiche e Gastroenterologiche; Unità di Gastroenterologia; Università di Padova; Padova Italy

4. Dipartimento di Medicina Interna; Unità di Gastroenterologia; IRCCS-Azienda Ospedaliera Universitaria San Martino-IST; Università di Genova; Genova Italy

5. Divisione di Chirurgia; Policlinico San Marco; Zingonia Italy

6. Unità di Medicina Interna e Gastroenterologia; Complesso Integrato Columbus; Università Cattolica di Roma; Roma Italy

7. Divisione di Medicina; Azienda Ospedaliera Bolognini; Seriate Italy

8. Unità Operativa di Gastroenterologia; Ospedale Belcolle; Viterbo Italy

9. Dipartimento di Gastroenterologia e Medicina Interna; Unità di Medicina Interna; Alma Mater Studiorum - Università di Bologna; Bologna Italy

10. Dipartimento di Medicina; Unità di Radiologia; Ospedale Fatebenefratelli; Milano Italy

11. Unità Operativa Gastroenterologia e Malattie del Ricambio; Azienda Ospedaliero-Universitaria Pisana; Pisa Italy

12. Dipartimento Biomedico di Medicina Interna e Specialistica; Unità di Gastroenterologia; Università di Palermo; Palermo Italy

13. Ospedale Regionale di Bolzano; Unità di Gastroenterologia; Bolzano Italy

14. Dipartimento di Medicina Clinica e Chirurgia; Unità di Gastroenterologia; Università di Napoli “Federico II”; Napoli Italy

15. Unità di Medicina Interna e Gastroenterologia; Policlinico Gemelli; Università Cattolica di Roma; Roma Italy

16. Clinica di Gastroenterologia; Università Politecnica delle Marche; Ancona Italy

17. Dipartimento di Medicina Interna; Ospedale per gli Infermi di Faenza; Faenza Italy

18. Unità di Malattie Infettive ed Epatologia; Azienda Ospedaliero-Universitaria di Parma; Parma Italy

19. Gastroenterology Unit; Ospedale Sacro Cuore Don Calabria; Negrar Italy

20. Dipartimento Biomedico di Medicina Interna e Specialistica; Unità di Medicina Interna 2; Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello; Palermo Italy

Funder

RFO funds of the Italian Ministry of the University and Research

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.13242/fullpdf

Reference38 articles.

1. Global cancer statistics;Jemal;CA Cancer J Clin,2011

2. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma;European Association for the Study of the Liver; European Organization for Research and Treatment of Cancer;J Hepatol,2012

3. Prognosis of hepatocellular carcinoma: the BCLC staging classification;Llovet;Semin Liver Dis,1999

4. Management of hepatocellular carcinoma: an update;Bruix;Hepatology,2011

5. Management of hepatocellular carcinoma in Japan: consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version;Kudo;Dig Dis,2011

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple asynchronous recurrence as a predictive factor for refractoriness against locoregional and surgical therapy in patients with intermediate-stage hepatocellular carcinoma;Scientific Reports;2024-05-13

2. Intermediate-stage hepatocellular carcinoma: refining substaging or shifting paradigm?;Journal of Liver Cancer;2024-03-31

3. Multidisciplinary Treatment of Hepatocellular Carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part I – Surgical treatments;Digestive and Liver Disease;2024-02

4. Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part II – Non-surgical treatments;Digestive and Liver Disease;2023-12

5. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept;The Lancet Oncology;2023-07